CA2672155C - Use of xanthohumol or isoxanthohumol as an active substance for the prevention and/or control of liver diseases - Google Patents

Use of xanthohumol or isoxanthohumol as an active substance for the prevention and/or control of liver diseases Download PDF

Info

Publication number
CA2672155C
CA2672155C CA2672155A CA2672155A CA2672155C CA 2672155 C CA2672155 C CA 2672155C CA 2672155 A CA2672155 A CA 2672155A CA 2672155 A CA2672155 A CA 2672155A CA 2672155 C CA2672155 C CA 2672155C
Authority
CA
Canada
Prior art keywords
body weight
xanthohumol
active substance
use according
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2672155A
Other languages
English (en)
French (fr)
Other versions
CA2672155A1 (en
Inventor
Claus Hellerbrand
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Flaxan GmbH and Co KG
Original Assignee
Flaxan GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Flaxan GmbH and Co KG filed Critical Flaxan GmbH and Co KG
Publication of CA2672155A1 publication Critical patent/CA2672155A1/en
Application granted granted Critical
Publication of CA2672155C publication Critical patent/CA2672155C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/121—Ketones acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3486—Humulus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
CA2672155A 2006-12-22 2007-12-21 Use of xanthohumol or isoxanthohumol as an active substance for the prevention and/or control of liver diseases Expired - Fee Related CA2672155C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102006062264.2 2006-12-22
DE102006062264A DE102006062264A1 (de) 2006-12-22 2006-12-22 Verwendung von Xanthohumol zur Vorbeugung und/oder Bekämpfung von Lebererkrankungen
PCT/EP2007/011358 WO2008077618A1 (de) 2006-12-22 2007-12-21 Verwendung von xanthohumol bzw. isoxanthohumol als wirkstoff zur vorbeugung und/oder bekämpfung von lebererkrankungen

Publications (2)

Publication Number Publication Date
CA2672155A1 CA2672155A1 (en) 2008-07-03
CA2672155C true CA2672155C (en) 2013-10-01

Family

ID=39186950

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2672155A Expired - Fee Related CA2672155C (en) 2006-12-22 2007-12-21 Use of xanthohumol or isoxanthohumol as an active substance for the prevention and/or control of liver diseases

Country Status (7)

Country Link
US (1) US20100029757A1 (enExample)
EP (1) EP2120906B1 (enExample)
JP (1) JP5513126B2 (enExample)
CA (1) CA2672155C (enExample)
DE (1) DE102006062264A1 (enExample)
RU (1) RU2454996C2 (enExample)
WO (1) WO2008077618A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9221751B2 (en) 2009-11-26 2015-12-29 Genfit Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
ES2441665T3 (es) * 2009-11-26 2014-02-05 Genfit Utilización de derivados de 1,3-difenilprop-2-en-1-ona para tratar trastornos hepáticos
US10722575B2 (en) 2009-11-26 2020-07-28 Genfit Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
WO2013191903A1 (en) 2012-06-18 2013-12-27 3M Innovative Properties Company Powder composition for air polishing the surface of hard dental tissue
BR112015001595A2 (pt) * 2012-07-26 2018-06-19 Ta-Xan Ag composição farmacêutica, uso de um extrato torrado, e, método para intensificar um ou mais efeito (s) terapêutico (s) de xantohumol e para a produção de uma composição farmacêutica
EP2931171B1 (en) 2012-12-17 2018-08-15 3M Innovative Properties Company Device for dispensing a dental material with locking mechanism
EP2742898A1 (en) 2012-12-17 2014-06-18 3M Innovative Properties Company Powder jet device for dispensing a dental material
EP2742897A1 (en) 2012-12-17 2014-06-18 3M Innovative Properties Company Nozzle head, hand piece and powder jet device for applying a dental material
US20180193287A1 (en) 2015-07-02 2018-07-12 John I. Haas, Inc. Hops-based substance and use of the substance
WO2018117041A1 (ja) * 2016-12-20 2018-06-28 サントリーホールディングス株式会社 イソキサントフモールを含む脂質代謝促進用組成物
ES2960296T3 (es) 2017-07-11 2024-03-04 Aquanova Ag Solubilizado con curcumina y boswelia y xantohumol
HRP20231146T1 (hr) * 2018-07-11 2024-01-05 Aquanova Ag Solubilizat ksantohumola
SG11202100265XA (en) * 2018-08-10 2021-02-25 Suntory Holdings Ltd Composition for promoting uric acid excretion, composition for inhibiting urat1 and composition for lowering blood uric acid level
EP3834629A4 (en) * 2018-08-10 2022-04-27 Suntory Holdings Limited COMPOSITION AND METHOD OF SUPPRESSING RAISED BLOOD SUGAR LEVELS
US20210322369A1 (en) * 2018-08-10 2021-10-21 Suntory Holdings Limited Composition for improving intestinal environment and method for improving intestinal flora
CN112584709A (zh) * 2018-08-10 2021-03-30 三得利控股株式会社 微生物增殖抑制剂、微生物污染防止方法及饮料
EP4291307A4 (en) 2021-02-09 2025-01-22 Oregon State University Xanthohumol derivatives and methods for making and using
EP4366723A4 (en) * 2021-07-09 2025-06-11 Innox Corp. COMPOSITIONS OF FLAVONOID AND PRENYLATED CHALCONES FOR USE IN THE TREATMENT OF CANCER

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07285856A (ja) 1994-04-21 1995-10-31 Hoechst Japan Ltd 骨粗鬆症治療剤
ES2235251T3 (es) * 1996-08-30 2005-07-01 Nps Pharmaceuticals, Inc. Isovaleramida destinada al tratamiento de convulsiones, epilepsia, dolor de cabeza y espacticidad.
AU6174900A (en) 1999-07-08 2001-01-30 Patrick T. Prendergast Use of flavones, coumarins and related compounds to treat infections
JP3293601B2 (ja) * 1999-09-03 2002-06-17 松下電器産業株式会社 管球およびその製造方法
EP1277473A4 (en) * 2000-04-10 2005-12-28 Takara Bio Inc REMEDIES
US20040156950A1 (en) * 2001-04-05 2004-08-12 Green Martin Richard Use of hop components in foods
US20040219238A1 (en) * 2001-07-13 2004-11-04 Eiji Nishiyama Remedies
DE10308864B4 (de) 2003-02-28 2007-03-01 Paulaner Brauerei Gmbh & Co. Kg Neues Brauverfahren, damit gebrautes Bier und dessen Verwendung
EP1543834A1 (en) 2003-12-16 2005-06-22 Biodynamics Production of hop extracts having oestrogenic and antiproliferative bioactivity
EP1861109A2 (en) * 2005-03-09 2007-12-05 Cardax Pharmaceuticals, Inc. Carotenoids, carotenoid analogs, or carotenoid derivatives for the treatment of proliferative disorders
JP2006306800A (ja) * 2005-04-28 2006-11-09 Kirin Brewery Co Ltd ファルネソイドｘ受容体活性化剤
EP1909584A4 (en) * 2005-07-29 2010-07-07 Bioactives Inc PRENYLFLAVONOID FORMULATIONS
EP2248532A1 (en) * 2005-08-09 2010-11-10 Metaproteomics, LLP Protein kinase modulation by hops and acacia products cross-reference to related applications
JP5246834B2 (ja) * 2005-12-27 2013-07-24 独立行政法人産業技術総合研究所 アディポネクチン産生強化剤

Also Published As

Publication number Publication date
RU2454996C2 (ru) 2012-07-10
JP2010513360A (ja) 2010-04-30
CA2672155A1 (en) 2008-07-03
US20100029757A1 (en) 2010-02-04
DE102006062264A1 (de) 2008-06-26
EP2120906A1 (de) 2009-11-25
RU2009128213A (ru) 2011-01-27
JP5513126B2 (ja) 2014-06-04
EP2120906B1 (de) 2015-04-22
WO2008077618A1 (de) 2008-07-03

Similar Documents

Publication Publication Date Title
US20100029757A1 (en) Use of xanthohumol and/or isoxanthohumol as an agent for preventing and/or combating liver diseases
CN101278928A (zh) 含左卡尼汀或其衍生物的药物组合物及其用途
KR100404303B1 (ko) 올티프라즈의 간섬유화 및 간경화 진행의 예방 및치료제로서의 용도 및 올티프라즈를 주성분으로 함유하는제약 조성물
EP3391893B1 (en) Pharmaceutical composition for treating leukemia and preparation method thereof
JP2005239581A (ja) 心筋炎の予防、治療又は改善用組成物
KR102187951B1 (ko) 녹각 영지버섯 추출물 및 퀘르세틴을 유효성분으로 포함하는 엡스타인 바 바이러스-양성 위암 치료용 약학적 조성물
JP2004091473A (ja) 色素沈着改善治療薬
US20140066519A1 (en) Use of xanthohumol and/or isoxanthohumol as an agent for preventing and/or combating liver diseases
CN102292081B (zh) 包含硫辛酸和羟基柠檬酸作为活性成分的药物联用物
CN106822152B (zh) 一种药物组合物及其应用
EP1263435B1 (en) Pharmaceutical composition for treatment and prevention of liver fibrosis and cirrhosis
KR101213599B1 (ko) 데커신 및/또는 데커시놀 안젤레이트, 또는 데커신및/또는 데커시놀 안젤레이트를 유효성분으로 하는당귀추출물을 포함하는 간기능 치료제 조성물
EP0722325A1 (fr) Composition pour le traitement ou la prevention de l'herpes
JP2018519342A (ja) ホップに基づく物質およびその物質の使用
KR100377789B1 (ko) 간섬유화 및 간경화 치료 및 예방용 의약 조성물
CN102076346A (zh) 一种人用药物组合物及铋或锌剂的制备
TWI624264B (zh) 南洋山蘇水萃物的用途
CN101194900A (zh) 桂皮醛在α-葡萄糖苷酶抑制剂中的应用
CN105816487A (zh) 五层龙的新用途
EP2958627A1 (en) Composition for the treatment of metabolic disorders
EP3829615A1 (en) Composition for oral administration comprising one or more cannabinoids
HK1204916B (zh) 淫羊藿苷元的医药用途
CN105832714A (zh) 牛磺酸在预防和/或治疗由冠状病毒属和/或轮状病毒属病毒引发的疾病中的应用
CN102552273A (zh) 含有表没食子儿茶素没食子酸酯与甲氨蝶呤的组合物

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20181221